MSLE Satellos Bioscience Inc. Common Stock
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.49
P/S
0.00
EV/EBITDA
-5.09
DCF Value
$7.03
FCF Yield
-23.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.4%
ROA
-25.6%
ROIC
-20.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-9.6M | $— |
| Q4 null | $0.00 | $-7.3M | $— |
| FY null | $0.00 | $-24.9M | $— |
| Q3 null | $0.00 | $-5.8M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$23.00 - $23.00
Company Info
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
CA
Exchange
—
Beta
1.19
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.